Kern Pharma

• NCT04836780

  Collaborator, Phase 3, Status unknown, 126 people, 8 Apr 2021

• Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study

  Fees or honoraria, 3 Sept 2026

• Pre-dementia clinical trajectories associated with neuronal α-synuclein neuropathologic change: a retrospective cohort study

  Fees or honoraria, 27 Aug 2026

• Cognitive Age Delta as a Marker of Healthy and Pathological Cognitive Aging: The Role of Lifestyle, Cognitive Reserve, and Vascular Risk

  Fees or honoraria, 18 Nov 2025

Sources: pubmed.ncbi.nlm.nih.gov